Atenção: Todas as denúncias são sigilosas e sua identidade será preservada.
Os campos nome e e-mail são de preenchimento opcional
Metadados | Descrição | Idioma |
---|---|---|
Autor(es): dc.contributor | Univ Minho | - |
Autor(es): dc.contributor | ICVS 3Bs PT Govt Associate Lab | - |
Autor(es): dc.contributor | Portuguese Inst Oncol | - |
Autor(es): dc.contributor | Univ Porto | - |
Autor(es): dc.contributor | Pccc | - |
Autor(es): dc.contributor | UFP | - |
Autor(es): dc.contributor | Universidade Estadual Paulista (Unesp) | - |
Autor(es): dc.contributor | Barretos Canc Hosp | - |
Autor(es): dc.creator | Afonso, Julieta | - |
Autor(es): dc.creator | Santos, Lucio L. | - |
Autor(es): dc.creator | Longatto-Filho, Adhemar [UNESP] | - |
Autor(es): dc.creator | Baltazar, Fatima | - |
Data de aceite: dc.date.accessioned | 2022-02-22T00:04:54Z | - |
Data de disponibilização: dc.date.available | 2022-02-22T00:04:54Z | - |
Data de envio: dc.date.issued | 2020-12-09 | - |
Data de envio: dc.date.issued | 2020-12-09 | - |
Data de envio: dc.date.issued | 2020-01-16 | - |
Fonte completa do material: dc.identifier | http://dx.doi.org/10.1038/s41585-019-0263-6 | - |
Fonte completa do material: dc.identifier | http://hdl.handle.net/11449/195141 | - |
Fonte: dc.identifier.uri | http://educapes.capes.gov.br/handle/11449/195141 | - |
Descrição: dc.description | Bladder cancer - the tenth most frequent cancer worldwide - has a heterogeneous natural history and clinical behaviour. The predominant histological subtype, urothelial bladder carcinoma, is characterized by high recurrence rates, progression and both primary and acquired resistance to platinum-based therapy, which impose a considerable economic burden on health-care systems and have substantial effects on the quality of life and the overall outcomes of patients with bladder cancer. The incidence of urothelial tumours is increasing owing to population growth and ageing, so novel therapeutic options are vital. Based on work by The Cancer Genome Atlas project, which has identified targetable vulnerabilities in bladder cancer, immune checkpoint inhibitors (ICIs) have arisen as an effective alternative for managing advanced disease. However, although ICIs have shown durable responses in a subset of patients with bladder cancer, the overall response rate is only similar to 15-25%, which increases the demand for biomarkers of response and therapeutic strategies that can overcome resistance to ICIs. In ICI non-responders, cancer cells use effective mechanisms to evade immune cell antitumour activity; the overlapping Warburg effect machinery of cancer and immune cells is a putative determinant of the immunosuppressive phenotype in bladder cancer. This energetic interplay between tumour and immune cells leads to metabolic competition in the tumour ecosystem, limiting nutrient availability and leading to microenvironmental acidosis, which hinders immune cell function. Thus, molecular hallmarks of cancer cell metabolism are potential therapeutic targets, not only to eliminate malignant cells but also to boost the efficacy of immunotherapy. In this sense, integrating the targeting of tumour metabolism into immunotherapy design seems a rational approach to improve the therapeutic efficacy of ICIs. | - |
Descrição: dc.description | Northern Portugal Regional Operational Programme (NORTE 2020) under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER) | - |
Descrição: dc.description | Northern Portugal Regional Operational Programme (NORTE 2020) under the Portugal Partnership Agreement, through Competitiveness Factors Operational Programme (COMPETE) | - |
Descrição: dc.description | Foundation for Science and Technology (FCT) | - |
Descrição: dc.description | FCT | - |
Descrição: dc.description | Univ Minho, Sch Med, Life & Hlth Sci Res Inst ICVS, Braga, Portugal | - |
Descrição: dc.description | ICVS 3Bs PT Govt Associate Lab, Braga, Portugal | - |
Descrição: dc.description | Portuguese Inst Oncol, IPO Porto Res Ctr, Expt Pathol & Therapeut Grp, Porto, Portugal | - |
Descrição: dc.description | Univ Porto, Inst Biomed Sci Abel Salazar, Porto, Portugal | - |
Descrição: dc.description | Pccc, Porto, Portugal | - |
Descrição: dc.description | UFP, Fac Hlth Sci, Porto, Portugal | - |
Descrição: dc.description | Sao Paulo State Univ, Fac Med, Lab Med Invest LIM 14, Sao Paulo, Brazil | - |
Descrição: dc.description | Barretos Canc Hosp, Mol Oncol Res Ctr, Sao Paulo, Brazil | - |
Descrição: dc.description | Sao Paulo State Univ, Fac Med, Lab Med Invest LIM 14, Sao Paulo, Brazil | - |
Descrição: dc.description | Northern Portugal Regional Operational Programme (NORTE 2020) under the Portugal Partnership Agreement, through the European Regional Development Fund (FEDER): NORTE-01-0145-FEDER-000013 | - |
Descrição: dc.description | Foundation for Science and Technology (FCT): POCI-01-0145-FEDER-007038 | - |
Descrição: dc.description | FCT: SFRH/BPD/116784/2016 | - |
Formato: dc.format | 77-106 | - |
Idioma: dc.language | en | - |
Publicador: dc.publisher | Nature Publishing Group | - |
Relação: dc.relation | Nature Reviews Urology | - |
???dc.source???: dc.source | Web of Science | - |
Título: dc.title | Competitive glucose metabolism as a target to boost bladder cancer immunotherapy | - |
Aparece nas coleções: | Repositório Institucional - Unesp |
O Portal eduCAPES é oferecido ao usuário, condicionado à aceitação dos termos, condições e avisos contidos aqui e sem modificações. A CAPES poderá modificar o conteúdo ou formato deste site ou acabar com a sua operação ou suas ferramentas a seu critério único e sem aviso prévio. Ao acessar este portal, você, usuário pessoa física ou jurídica, se declara compreender e aceitar as condições aqui estabelecidas, da seguinte forma: